drugset / Trial / NCT07223502
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
Timeline
- Start
- 2025-05-01
- Primary completion
- 2026-09-17
- Completion
- 2026-09-17
Outcome
Outcome not reported
Stopped (Enrollment): “No recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Finerenone | Small molecule | 10 mg | Oral |
| Comparator | Spironolactone | Small molecule | 30 mg | — |
| Comparator | Torsemide | Other / unclassified | 24 mg | — |
| Comparator | Furosemide | Other / unclassified | 80 mg | Oral |